Bellone S

No ORCID on file · 8 papers in corpus · active 2010-2025

Study types

  • other 2

Condition tags

  • endometriosis 2
other 2025
TET3 is a common epigenetic immunomodulator of pathogenic macrophages
The Journal of clinical investigation ·doi:10.1172/JCI194879

Through a combination of single-cell/single-nucleus RNA-Seq (sc/snRNA-Seq) data analysis, immunohistochemistry, and primary macrophage studies, we have identified pathogenic macrophages characterized by Tet methylcytosine dioxygenase 3 (TET…

2024
Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.
Gynecologic oncology reports ·doi:10.1016/j.gore.2024.101324

Up to 30 % of COVID-infected patients may develop post-acute sequelae of COVID-19 (PASC), also known as Long COVID (LC), a syndrome characterized by a variety of debilitating symptoms lasting for more than 3 months after the acute infection…

other 2024
TET3-overexpressing macrophages promote endometriosis
The Journal of clinical investigation ·doi:10.1172/JCI181839

Endometriosis is a debilitating, chronic inflammatory disease affecting approximately 10% of reproductive-age women worldwide with no cure. While macrophages have been intrinsically linked to the pathophysiology of endometriosis, targeting …

2020
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2020.06.484

ObjectiveWhole-exome-sequencing (WES) studies reported c-MYC gene-amplification and HUWE1 gene deletion/mutations in a significant number of cervical-cancer-patients (CC) suggesting HUWE1/c-MYC pathway as potential therapeutic target. We in…

2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.03.050

IntroductionSince the majority of patients are diagnosed at an advanced stage, ovarian cancer remains the most lethal gynecologic malignancy. There is no single biomarker with the sensitivity and specificity required for effective cancer sc…

2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-18-0864

Purpose: Uterine serous carcinoma (USC) is a rare and aggressive variant of endometrial cancer. Whole-exome sequencing (WES) studies have recently reported c-Myc gene amplification in a large number of USCs, suggesting c-Myc as a potential …

2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Clinical & experimental metastasis ·doi:10.1007/s10585-011-9401-0

We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. We studied the expres…

2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
British journal of cancer ·doi:10.1038/sj.bjc.6605760

BackgroundUterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human…